Results 181 to 190 of about 276,615 (314)
Humoral antibodies and coagulation mechanisms in the accelerated or hyperacute rejection of renal homografts in sensitized canine recipients. [PDF]
Amemiya, H +9 more
core
Selenomethionine can ameliorate arachidonic acid‐induced colonic injury through synergistic mechanisms, including alleviating inflammatory responses, improving barrier integrity, enhancing antioxidant capacity by upregulating selenoprotein expression, selectively regulating AA metabolism to reduce pro‐inflammatory oxylipins and promote the production ...
Huihui Tian +8 more
wiley +1 more source
A summary of the status of de novo cancer in transplant recipients. [PDF]
Penn, I, Starzl, TE
core
Antimicrobial resistance (AMR) is an escalating global threat driven by antimicrobial use in aquaculture and livestock. Resistant pathogens and genes can spread across humans, animals, and the environment through interconnected ecosystems. Using a One Health approach, this review emphasizes antimicrobial stewardship, regulatory strengthening, enhanced ...
Mir Mohammad Ali +10 more
wiley +1 more source
Skin Organoids in Diabetic Chronic Wounds: Current Status and Future Perspectives. [PDF]
Wang Z, Hou M, Pei J, Gao F, Li Z.
europepmc +1 more source
Chimerism after whole organ transplantation: an explanation of renal and other organ acceptance [PDF]
Demetris, AJ +5 more
core
Objective High‐intensity conditioning autologous hematopoietic stem cell transplantation (AHSCT) is standard of care for patients with advanced systemic sclerosis (SSc). The role of reduced‐intensity conditioning (RIC) before AHSCT in this population remains unclear.
Yonatan Lean +4 more
wiley +1 more source
Oncology and Solid Organ Transplantation: New Biological and Clinical Insights. [PDF]
Zaza G +6 more
europepmc +1 more source
The influence of donor and recipient strains in isolated small bowel transplantation in rats [PDF]
Demetris, AJ +9 more
core
Objective The treatment landscape for systemic sclerosis‐associated interstitial lung disease (SSc‐ILD) has evolved with increasingly available immunosuppressive therapies (ISTs) and antifibrotic treatments. However, their real‐world use remains unclear.
Corrado Campochiaro +17 more
wiley +1 more source

